EGFR-IN-33 

EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13)^[1].

488.97

C₂₆H₂₅ClN₆O₂

2711105-59-6

C=CC(N1CCCC(C1)C2=CN(C3=C(N=CN=C23)N)C4=CC=C(C(Cl)=C4)OCC5=CC=CC=N5)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yihan Wang, et al. Substituted acrylamide derivatives and compositions thereof and their uses. Patent WO2021185348A1.